Faeth Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Faeth Therapeutics, Inc. (FTH) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $247.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-04
- Faeth Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $351.00K.
- Faeth Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$104.00K, a 109.38% decline year-over-year.
- Faeth Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $77.00K.
- Faeth Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $269.00K, a 796.67% increase year-over-year.
- Faeth Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $233.00K.
- Faeth Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$445.00K.
- Faeth Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was -$2.33M, a 215.57% decline from fiscal 2022.
- Faeth Therapeutics, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $2.02M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $351.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $247.00K 10-Q · filed 2026-08-04 | $324.00K derived: sum of 3 quarters · filed 2026-08-04 | $593.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$104.00K 10-Q · filed 2026-05-15 | -$27.00K derived: sum of 2 quarters · filed 2026-05-15 | $242.00K derived: sum of 3 quarters · filed 2026-05-15 | -$980.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $346.00K derived: sum of 2 quarters · filed 2026-03-30 | -$876.00K derived: sum of 3 quarters · filed 2026-08-04 | $233.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $269.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$953.00K derived: sum of 2 quarters · filed 2026-08-04 | $156.00K 10-Q · filed 2025-11-14 | -$271.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$113.00K 10-Q · filed 2026-08-04 | -$540.00K derived: sum of 3 quarters · filed 2026-08-04 | -$510.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $1.11M 10-Q · filed 2026-05-15 | $682.00K derived: sum of 2 quarters · filed 2026-05-15 | $712.00K derived: sum of 3 quarters · filed 2026-05-15 | $358.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$427.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$397.00K derived: sum of 2 quarters · filed 2026-03-30 | -$751.00K derived: sum of 3 quarters · filed 2026-03-30 | -$445.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$324.00K derived: sum of 2 quarters · filed 2025-11-14 | -$18.00K 10-Q · filed 2025-11-14 | -$799.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$354.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$48.00K 10-Q · filed 2025-08-05 | -$829.00K derived: sum of 3 quarters · filed 2025-08-05 | -$358.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $306.00K 10-Q · filed 2025-05-06 | -$475.00K derived: sum of 2 quarters · filed 2025-05-06 | -$4.00K derived: sum of 3 quarters · filed 2025-05-06 | -$2.27M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$781.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$310.00K derived: sum of 2 quarters · filed 2025-03-28 | -$2.57M derived: sum of 3 quarters · filed 2025-03-28 | -$2.33M 10-K · filed 2025-03-28 |
| 2023-09-30 | $471.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$1.79M derived: sum of 2 quarters · filed 2024-11-14 | -$1.55M 10-Q · filed 2024-11-14 | -$1.73M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$2.02M 10-Q · filed 2024-08-06 | -$2.21M derived: sum of 3 quarters · filed 2024-08-06 | $29.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $242.00K 10-Q · filed 2024-05-09 | $58.00K derived: sum of 2 quarters · filed 2024-05-09 | $2.29M derived: sum of 3 quarters · filed 2024-05-09 | -$385.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$184.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $2.05M derived: sum of 2 quarters · filed 2024-02-29 | -$627.00K derived: sum of 3 quarters · filed 2024-02-29 | $2.02M 10-K · filed 2024-02-29 |
| 2022-09-30 | $2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$443.00K derived: sum of 2 quarters · filed 2023-11-07 | $2.20M 10-Q · filed 2023-11-07 | $1.18M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$2.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$33.00K 10-Q · filed 2023-08-03 | -$1.05M derived: sum of 3 quarters · filed 2023-08-03 | -$311.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $2.64M 10-Q · filed 2023-05-09 | $1.63M derived: sum of 2 quarters · filed 2023-05-09 | $2.37M derived: sum of 3 quarters · filed 2023-05-09 | $3.10M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$278.00K derived: sum of 2 quarters · filed 2023-03-29 | $454.00K derived: sum of 3 quarters · filed 2023-03-29 | -$1.43M 10-K · filed 2023-03-29 |
| 2021-09-30 | $740.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.47M derived: sum of 2 quarters · filed 2022-11-08 | -$408.00K 10-Q · filed 2022-11-08 | $2.40M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $732.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$1.15M 10-Q · filed 2022-08-09 | $1.66M derived: sum of 3 quarters · filed 2022-08-09 | -$860.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$1.88M 10-Q · filed 2022-05-10 | $932.00K derived: sum of 2 quarters · filed 2022-05-10 | -$1.59M derived: sum of 3 quarters · filed 2022-05-10 | -$441.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $288.00K derived: sum of 2 quarters · filed 2022-03-15 | $1.44M derived: sum of 3 quarters · filed 2022-03-15 | $335.00K 10-K · filed 2022-03-15 |
| 2020-09-30 | -$2.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$1.37M derived: sum of 2 quarters · filed 2021-11-10 | -$2.48M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $47.00K 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | -$1.10M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |